Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-072)
NCT ID: NCT00111722
Last Updated: 2024-08-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
393 participants
INTERVENTIONAL
2005-05-27
2006-02-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-071)
NCT00111709
Study to Test an Approved Product in the Early Treatment of Migraine (0462-065)
NCT00092963
Study to Test Rizatriptan in the Early Treatment of Acute Migraine (0462-081)
NCT00516737
Study to Test an Approved Product in the Early Treatment of Migraine (0462-066)
NCT00095004
Treatment of Multiple Attacks of Acute Migraine (0462-025)
NCT00899379
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MK0462, rizatriptan benzoate / Duration of Treatment -1day
Comparator: placebo / Duration of Treatment - 1 day
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient has menses approximately monthly
* Patient has at least a 6 month history of migraine and at least a 6 month history of menstrual migraine
Exclusion Criteria
* Cardiovascular disease
* Uncontrolled hypertension
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Organon and Co
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Monitor
Role: STUDY_DIRECTOR
Merck Sharp & Dohme LLC
References
Explore related publications, articles, or registry entries linked to this study.
Mannix LK, Loder E, Nett R, Mueller L, Rodgers A, Hustad CM, Ramsey KE, Skobieranda F. Rizatriptan for the acute treatment of ICHD-II proposed menstrual migraine: two prospective, randomized, placebo-controlled, double-blind studies. Cephalalgia. 2007 May;27(5):414-21. doi: 10.1111/j.1468-2982.2007.01313.x.
Nett R, Mannix LK, Mueller L, Rodgers A, Hustad CM, Skobieranda F, Ramsey KE. Rizatriptan efficacy in ICHD-II pure menstrual migraine and menstrually related migraine. Headache. 2008 Sep;48(8):1194-201. doi: 10.1111/j.1526-4610.2008.01093.x. Epub 2008 Apr 14.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2005_025
Identifier Type: -
Identifier Source: secondary_id
0462-072
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.